课题基金 / 基金详情

I-Corps: Fabrication of accurate and realistic anatomical models for medical education, training, and medical device development

I-Corps: Fabrication of accurate and realistic anatomical models for medical education, training, and medical device development
I-Corps:为医学教育、培训和医疗设备开发制作准确、真实的解剖模型
批准号:
1930677
负责人:
Fluvio Lobo Fenoglietto
金额:
$5.0万
依托单位国家:
美国
项目类别:
Standard Grant
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-06-15 至 2020-12-31

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
该I-Corps项目的更广泛影响和商业潜力包括目前为医学教育、培训、手术计划和医疗器械开发制造的所有人体组织模型。医学生、住院医生、外科医生和内科医生都依赖由硅树脂、橡胶、普通塑料和泡沫制成的人体模拟器和部分任务训练器。训练器用于插管、插管、腹腔镜手术等。已知模拟器材料和人体组织之间的差异会诱导负面训练。为了满足这一需求,医疗专业人员和医疗设备工程师依赖于动物和尸体模型。这些模型是昂贵的,不可靠的,并需要额外的协议处理和处置。缺乏一个解决方案,巩固解剖和物理现实主义导致医生和工程师得出结论,从几个不切实际的实验结果插值。这个I-Corps项目旨在通过开发和打印患者或病例特异性的高保真人体组织模型来巩固和满足这些需求。这些模型可能会颠覆医疗模拟和医疗设备开发市场(分别为13.6亿美元和3000亿美元)。3D建模和3D打印制造商最近获得了FDA 510(k)批准,用于患者数据建模和制造,这表明医疗需求不断增长。这个I-Corps项目的前提是,异质复合结构在自然界中会产生特定的物理特性。例如,为了复制人体组织的非线性力学,必须设计类似于组织微观结构的复合材料。I-Corps团队开发了一种自动设计和制造具有可调物理性能的复合材料的方法并获得专利(美国专利号10,073,440)。该团队的专利组合包括基础专利的三个延续。该方法将增材制造的范式从复制形式转变为重新创建功能和物理行为。最先进的增材制造系统采用多种材料,具有不同的颜色和顺应性,以及微米分辨率。依靠具有已知特性的几何形状库,该方法可以通过重复设计参数和材料组合来近似输入或目标材料的物理响应。该方法建立在自身之上,因为每次迭代都为未来的目标扩展解决方案库。该奖项反映了NSF的法定使命,并通过使用基金会的知识价值和更广泛的影响审查标准进行评估,被认为值得支持。
英文摘要
The broader impact and commercial potential of this I-Corps project encompasses all human tissue models currently manufactured for medical education, training, surgical planning, and medical device development. Medical students, residents, surgical fellows, and physicians rely on human simulators and part-task trainers made out of silicones, rubbers, common plastics, and foams. Trainers are used for suturing, intubation, laparoscopic surgery, among others. The disparity between simulator materials and human tissues has been known to induce negative training. To satisfy this need, medical professionals and medical device engineers rely on animal and cadaveric models. These models are expensive, unreliable, and require additional protocols for handling and disposal. The lack of a solution that consolidates anatomical and physical realism leads physicians and engineers to draw conclusions by interpolating findings from several, unrealistic experiments. This I-Corps project seeks to consolidate and satisfy these needs through the development and printing of patient- or case-specific, high fidelity human tissue models. These models could disrupt the medical simulation and medical device development markets ($1.36 billion and $300 billion respectively). 3D modeling and 3D printing manufacturers have recently received FDA 510(k) clearance for patient data modeling and fabrication, indicative of a growing medical demand.This I-Corps project is based on the premise that heterogeneous, composite structures give rise to particular physical properties in nature. In order to replicate the non-linear mechanics of human tissues for instance, composites that resemble the microstructure of tissues must be designed. The I-Corps team has developed and patented a method for the automated design and fabrication of composites with tunable physical properties (U.S. Patent No. 10,073,440). The team's patent portfolio includes three continuations to the base patent. The method shifts the paradigm of additive manufacturing from replicating form to recreating function, physical behavior. The most advanced additive manufacturing systems feature multiple materials, with varying color and compliance, and micrometer resolution. Relying on a library of geometries with known characteristics, the method can approximate the physical response of an input or target material by re-iterating through design parameters and material combination. The method builds upon itself, as each iteration expands the libraries of solutions for future targets. The resulting composite structures cannot be fabricated using traditional methods.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金